Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludarabine Phosphate in Mediastinal large B-cell lymphoma: NCT06486051 Clinical Landscape Report 2026
16 October 2026
NCT06486051 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Umbilical cord mesenchymal stem cells(Chinese PLA General Hospital) in Lupus Nephritis: NCT06485648 Clinical Landscape Report 2026
16 October 2026
NCT06485648 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NM-135 in Idiopathic Inflammatory Myopathies: ACTRN12624000817549 Clinical Landscape Report 2026
16 October 2026
ACTRN12624000817549 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Nivolumab in Melanoma, Cutaneous Malignant: NCT06488482 Clinical Landscape Report 2026
16 October 2026
NCT06488482 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Osteosarcoma, Recurrent: NCT06492954 Clinical Landscape Report 2026
16 October 2026
NCT06492954 clinical landscape for Osteosarcoma, Recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ascorbic Acid in Muscle Invasive Bladder Carcinoma: NCT06493370 Clinical Landscape Report 2026
16 October 2026
NCT06493370 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Pembrolizumab in Soft Tissue Sarcoma: NCT06494787 Clinical Landscape Report 2026
16 October 2026
NCT06494787 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Bladder Cancer: NCT06488222 Clinical Landscape Report 2026
16 October 2026
NCT06488222 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
sEphB4-HSA in Muscle Invasive Bladder Carcinoma: NCT06493552 Clinical Landscape Report 2026
16 October 2026
NCT06493552 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Ribrecabtagene autoleucel in Lupus Nephritis: NCT06497387 Clinical Landscape Report 2026
16 October 2026
NCT06497387 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in Uterine Neoplasms: CTRI/2024/07/070458 Clinical Landscape Report 2026
16 October 2026
CTRI/2024/07/070458 clinical landscape for Uterine Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19/BCMA CAR-T (Shenzhen Puruijin Biological Pharma) in Lupus Nephritis: NCT06497361 Clinical Landscape Report 2026
16 October 2026
NCT06497361 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.